Terms: = Lung cancer AND NOTCH2, Q04721, 4853, ENSG00000134250, AGS2, hN2 AND Treatment
16 results:
1. Notch signaling and targeted therapy in non-small cell lung cancer.
Sun J; Dong M; Xiang X; Zhang S; Wen D
Cancer Lett; 2024 Mar; 585():216647. PubMed ID: 38301911
[TBL] [Abstract] [Full Text] [Related]
2. Down-regulated NEDD4L facilitates tumor progression through activating Notch signaling in lung adenocarcinoma.
Lin L; Wu X; Jiang Y; Deng C; Luo X; Han J; Hu J; Cao X
PeerJ; 2022; 10():e13402. PubMed ID: 35646490
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract] [Full Text] [Related]
4. Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell lung cancer.
Fushimi A; Morimoto Y; Ishikawa S; Yamashita N; Bhattacharya A; Daimon T; Rajabi H; Jin C; Hagiwara M; Yasumizu Y; Luan Z; Suo W; Wong KK; Withers H; Liu S; Long MD; Kufe D
Mol Cancer Res; 2022 Sep; 20(9):1379-1390. PubMed ID: 35612556
[TBL] [Abstract] [Full Text] [Related]
5. Regulation of miRNA Biogenesis and Histone Modification by K63-Polyubiquitinated DDX17 Controls cancer Stem-like Features.
Kao SH; Cheng WC; Wang YT; Wu HT; Yeh HY; Chen YJ; Tsai MH; Wu KJ
Cancer Res; 2019 May; 79(10):2549-2563. PubMed ID: 30877109
[TBL] [Abstract] [Full Text] [Related]
6. miR-181b/notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC.
Wang X; Meng Q; Qiao W; Ma R; Ju W; Hu J; Lu H; Cui J; Jin Z; Zhao Y; Wang Y
Stem Cell Res Ther; 2018 Nov; 9(1):327. PubMed ID: 30470250
[TBL] [Abstract] [Full Text] [Related]
7. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival.
Xie M; Wei S; Wu X; Li X; You Y; He C
Lung Cancer; 2018 Jul; 121():41-47. PubMed ID: 29858025
[TBL] [Abstract] [Full Text] [Related]
8. Advances in antibody therapeutics targeting small-cell lung cancer.
Lu H; Jiang Z
Adv Clin Exp Med; 2018 Sep; 27(9):1317-1323. PubMed ID: 29790694
[TBL] [Abstract] [Full Text] [Related]
9. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
10. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell lung cancer Reveals Dynamic Insights into treatment Efficacy and Disease Relapse.
Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
[TBL] [Abstract] [Full Text] [Related]
11. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
[TBL] [Abstract] [Full Text] [Related]
12. Targeting Notch signaling with a notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
Yen WC; Fischer MM; Axelrod F; Bond C; Cain J; Cancilla B; Henner WR; Meisner R; Sato A; Shah J; Tang T; Wallace B; Wang M; Zhang C; Kapoun AM; Lewicki J; Gurney A; Hoey T
Clin Cancer Res; 2015 May; 21(9):2084-95. PubMed ID: 25934888
[TBL] [Abstract] [Full Text] [Related]
13. Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy.
Egloff AM; Grandis JR
Clin Cancer Res; 2012 Oct; 18(19):5188-95. PubMed ID: 22773520
[TBL] [Abstract] [Full Text] [Related]
14. Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis.
Garnis C; Campbell J; Davies JJ; Macaulay C; Lam S; Lam WL
Hum Mol Genet; 2005 Feb; 14(4):475-82. PubMed ID: 15615770
[TBL] [Abstract] [Full Text] [Related]
15. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.
Frei E; Holden SA; Gonin R; Waxman DJ; Teicher BA
Cancer Chemother Pharmacol; 1993; 33(2):113-22. PubMed ID: 8261570
[TBL] [Abstract] [Full Text] [Related]
16. Trisethylene-imino-s-triazine (triethylene melamine or TEM) in the treatment of neoplastic diseases.
SHIMKIN MB; BIERMAN HR; KELLY KH; LOWENHAUPT E; FURST A
Calif Med; 1951 Jul; 75(1):26-34. PubMed ID: 14848718
[TBL] [Abstract] [Full Text] [Related]
